Twelve weeks of therapy with the farnesoid X receptor (FXR) agonist tropifexor (Novartis) produces dose-dependent reductions in liver fat and function in patients with fibrotic non-alcoholic steatohepatitis, new research has concluded.
Although higher doses of the novel agent were associated with mild pruritus, tropifexor was otherwise well tolerated over the three-month study period.
“Tropifexor is a novel and potent farnesoid X receptor agonist that has been shown to be efficacious in